Monthly Archives: August 2018

28 August 2018

Arago Bioscience – University of Oxford Innovation Fund IV investment

By |August 28th, 2018|

We are delighted to announce that the University of Oxford Innovation Fund IV has invested in Arago Biosciences alongside Oxford Sciences Innovation. Arago has designed the world’s most sensitive light microscope.

Arago Biosciences, a spin-out company from the University of Oxford’s Department of Chemistry, has designed a new way of detecting and quantifying molecules. The […]

Astellas announces acquisition of Quethera

By |August 10th, 2018|

Astellas Pharma Inc. and Quethera Limited announced that Astellas has acquired Quethera, a gene therapy company headquartered in the United Kingdom that is focused on developing novel treatments for ocular disorders, such as glaucoma.

Through this transaction, Astellas has acquired Quethera’s ophthalmic gene therapy program, which uses a recombinant adeno-associated viral vector system (rAAV) to introduce […]

University of Cambridge Enterprise Fund VI launched

By |August 3rd, 2018|

Parkwalk are delighted to announce the launch of the University of Cambridge Enterprise Fund VI.

Launched in conjunction with Cambridge Enterprise, the University’s Technology Transfer and academic consulting subsidiary, the University of Cambridge Enterprise Funds offer alumni and investors the opportunity to invest in companies formed to develop and commercialise technology and intellectual property developed at the University of Cambridge in […]

Ilika – Parkwalk investment

By |August 1st, 2018|

We are delighted to announce that the Parkwalk Opportunities EIS Fund has participated in a £4.4m funding round in Ilika, an AIM listed company which specialises in materials innovation. The company has developed unique solid state battery technology which may have applications across the Internet of Things (IoT).

Ilika spun out of the University of […]